Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Abstract Text:

Michal Sieniawski,Thorsten Reineke,Lucia Nogova,Andreas Josting,Beate Pfistner,Volker Diehl,Andreas Engert,Michal Sieniawski,Thorsten Reineke,Lucia Nogova,Andreas Josting,Beate Pfistner,Volker Diehl,Andreas Engert,Michal Sieniawski,Thorsten Reineke,Lucia Nogova,Andreas Josting,Beate Pfistner,Volker Diehl,Andreas Engert,

To date, there is little information on the impact of more aggressive treatment regimen such as BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone) on the fertility of male patients with Hodgkin lymphoma (HL). We evaluated the impact of BEACOPP regimen on fertility status in 38 male patients with advanced-stage HL enrolled into trials of the German Hodgkin Study Group (GHSG). Before treatment, 6 (23%) patients had normozoospermia and 20 (77%) patients had dysspermia. After treatment, 34 (89%) patients had azoospermia, 4 (11%) had other dysspermia, and no patients had normozoospermia. There was no difference in azoospermia rate between patients treated with BEACOPP baseline and those given BEACOPP escalated (93% vs 87%, respectively; P > .999). After treatment, most of patients (93%) had abnormal values of follicle-stimulating hormone, whereas the number of patients with abnormal levels of testosterone and luteinizing hormone was less pronounced-57% and 21%, respectively. In univariate analysis, none of the evaluated risk factors (ie, age, clinical stage, elevated erythrocyte sedimentation rate, B symptoms, large mediastinal mass, extranodal disease, and 3 or more lymph nodes) was statistically significant. Male patients with HL are at high risk of infertility after treatment with BEACOPP.

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Publishing Authors By Initials

M Sieniawski,T Reineke,L Nogova,A Josting,B Pfistner,V Diehl,A Engert,M Sieniawski,T Reineke,L Nogova,A Josting,B Pfistner,V Diehl,A Engert,M Sieniawski,T Reineke,L Nogova,A Josting,B Pfistner,V Diehl,A Engert,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Blood

VOLUME: 111

Page Numbers: 71-6

Journal Abbreviation: Blood

ISSN: 0006-4971

DAY: 21

MONTH: 09

YEAR: 2007

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7603509

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG). Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).

AFFILIATION:

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Blood

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group GHSG Related Publications

• Assessment of male fertility in patients with Hodgkin's lymphoma treated in the German Hodgkin Study Group (GHSG) clinical trials.
• Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
• Chemotherapy plus Rituximab versus chemotherapy alone for B-cell non-Hodgkin's lymphoma.
• Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG).
• Control of visually guided behavior by distinct populations of spinal projection neurons.
• Current treatment strategies of the German Hodgkin Study Group (GHSG).
• Differences in hematotoxicity between male and female patients with Hodgkin lymphoma and other malignancies.
• Eighth biannual report of the Cochrane Haematological Malignancies Group--focus on chronic lymphatic leukemia.
• Escape behavior elicited by single, channelrhodopsin-2-evoked spikes in zebrafish somatosensory neurons.
• Familial combined hyperlipidaemia: how can genetic disorders be common, complex and comprehensible?
• Fertility in male patients with advanced Hodgkin lymphoma treated with BEACOPP: a report of the German Hodgkin Study Group (GHSG).
• Genetic Variants of FTO Influence Adiposity, Insulin Sensitivity, Leptin Levels, and Resting Metabolic Rate in the Quebec Family Study.
• Granulopoiesis-stimulating factors to prevent adverse effects in the treatment of malignant lymphoma.
• High-dose chemotherapy with autologous stem cell transplantation in the first line treatment of aggressive Non-Hodgkin Lymphoma (NHL) in adults.
• Hodgkin's disease. Future treatment strategies: fact or fiction?
• Human Leukocyte Antigen-B-Associated Transcript 3 Is Released from Tumor Cells and Engages the NKp30 Receptor on Natural Killer Cells.
• Immunotherapy of Hodgkin's lymphoma.
• K45R variant of squalene synthase increases total cholesterol levels in two study samples from a French Canadian population.
• Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
• Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
• Non-Hodgkin's Lymphoma: A Review of Immunotherapeutic Approaches to Treatment.
• Yttrium-90 ibritumomab tiuxetan-induced complete remission in a patient with classical lymphocyte-rich Hodgkin's Lymphoma.
• [Antibiotic therapy of endocarditis lenta.]
• [Effect of intraoperative blood loss on the function of natural killer cells in tumors of the upper gastrointestinal tract]
• [Thoracic surgery emergencies in early childhood]